Raymond James Financial Services Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$21.2M Sell
252,749
-14,974
-6% -$1.14M 0.03% 528
2024
Q2
$18.4M Sell
267,723
-64,635
-19% -$4.31M 0.03% 546
2024
Q1
$24.3M Buy
332,358
+36,037
+12% +$2.77M 0.04% 438
2023
Q4
$24M Buy
296,321
+45,272
+18% +$3.52M 0.04% 420
2023
Q3
$18.8M Sell
251,049
-18,436
-7% -$1.42M 0.03% 472
2023
Q2
$20.8M Sell
269,485
-25,114
-9% -$2M 0.04% 455
2023
Q1
$24.4M Buy
294,599
+47,644
+19% +$3.95M 0.05% 379
2022
Q4
$21.2M Sell
246,955
-24,948
-9% -$1.98M 0.04% 413
2022
Q3
$16.8M Buy
271,903
+7,917
+3% +$499K 0.04% 434
2022
Q2
$16.3M Sell
263,986
-29,424
-10% -$1.82M 0.04% 459
2022
Q1
$17.4M Buy
293,410
+43,788
+18% +$2.8M 0.03% 487
2021
Q4
$18.1M Sell
249,622
-43,946
-15% -$3.03M 0.03% 483
2021
Q3
$20.5M Sell
293,568
-20,760
-7% -$1.46M 0.04% 437
2021
Q2
$21.6M Buy
314,328
+31,699
+11% +$2.12M 0.04% 416
2021
Q1
$18.3M Sell
282,629
-4,355
-2% -$281K 0.04% 427
2020
Q4
$16.7M Sell
286,984
-40,353
-12% -$2.43M 0.04% 410
2020
Q3
$20.7M Sell
327,337
-81,981
-20% -$5.69M 0.06% 312
2020
Q2
$31.5M Sell
409,318
-57,118
-12% -$4.38M 0.1% 213
2020
Q1
$34.9M Buy
466,436
+121,117
+35% +$8.37M 0.15% 140
2019
Q4
$22.4M Buy
345,319
+32,405
+10% +$2.11M 0.07% 279
2019
Q3
$19.8M Buy
312,914
+62,845
+25% +$4.11M 0.07% 288
2019
Q2
$16.9M Sell
250,069
-10,245
-4% -$674K 0.06% 323
2019
Q1
$16.9M Sell
260,314
-4,542
-2% -$302K 0.07% 307
2018
Q4
$16.6M Buy
264,856
+1,711
+0.7% +$120K 0.09% 252
2018
Q3
$20.3M Buy
263,145
+40,087
+18% +$3.03M 0.09% 250
2018
Q2
$15.8M Sell
223,058
-79,816
-26% -$5.64M 0.08% 281
2018
Q1
$22.8M Buy
302,874
+15,459
+5% +$1.23M 0.13% 170
2017
Q4
$20.6M Buy
287,415
+4,022
+1% +$305K 0.13% 176
2017
Q3
$23M Sell
283,393
-4,942
-2% -$378K 0.15% 153
2017
Q2
$20.4M Buy
288,335
+38,044
+15% +$2.53M 0.14% 162
2017
Q1
$17M Sell
250,291
-26,773
-10% -$1.88M 0.13% 187
2016
Q4
$19.8M Sell
277,064
-20,076
-7% -$1.49M 0.17% 138
2016
Q3
$23.5M Buy
297,140
+27,273
+10% +$2.22M 0.21% 116
2016
Q2
$22.5M Sell
269,867
-13,758
-5% -$1.22M 0.22% 113
2016
Q1
$26.1M Buy
283,625
+9,123
+3% +$823K 0.3% 74
2015
Q4
$27.8M Buy
274,502
+30,234
+12% +$3.15M 0.33% 69
2015
Q3
$24M Buy
244,268
+139,266
+133% +$15.5M 0.4% 51
2015
Q2
$12.3M Buy
+105,002
New +$11.5M 0.88% 18
2014
Q3
Sell
-13,126
Closed -$1.09M 554
2014
Q2
$1.09M Sell
13,126
-213
-2% -$16.6K 0.06% 314
2014
Q1
$945K Buy
13,339
+276
+2% +$21.6K 0.06% 340
2013
Q4
$981K Sell
13,063
-2,300
-15% -$160K 0.06% 316
2013
Q3
$966K Sell
15,363
-63,441
-81% -$3.79M 0.06% 311
2013
Q2
$4.04M Buy
+78,804
New +$4.11M 0.12% 203

Other funds holding GILD

Raymond James Financial Services Advisors's GILD Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Gilead Sciences (GILD) stake by 5.6% in Q3 2024, selling an estimated $1.14M and leaving 252,749 shares worth $21.2M. The position accounts for 0.03% of the portfolio, ranked #528.

Raymond James Financial Services Advisors first reported a position in GILD in Q2 2013 and has held it in 43 quarters since. The position peaked at $34.9M in Q1 2020. 1,719 funds tracked by Wall St. Rank hold GILD as of Q3 2024.

  • Raymond James Financial Services Advisors held 252,749 shares of Gilead Sciences worth $21.2M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 14,974 Gilead Sciences shares in Q3 2024, an estimated $1.14M.
  • Gilead Sciences made up 0.03% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #528 holding.
  • Raymond James Financial Services Advisors first reported a position in Gilead Sciences in Q2 2013 and has held it in 43 quarters since.
  • Raymond James Financial Services Advisors's Gilead Sciences position peaked at $34.9M in Q1 2020.
  • 1,719 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.